Sera Prognostics (NASDAQ:SERA) Releases Earnings Results, Misses Estimates By $0.02 EPS

Sera Prognostics (NASDAQ:SERA) issued its earnings results on Wednesday. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02), Zacks reports. During the same period last year, the firm earned ($0.25) EPS.

Sera Prognostics Price Performance

Shares of NASDAQ:SERA traded up $0.06 during trading on Wednesday, reaching $4.14. 57,117 shares of the company were exchanged, compared to its average volume of 142,782. The firm has a market capitalization of $139.82 million, a PE ratio of -4.18 and a beta of 0.89. The business’s fifty day simple moving average is $5.15 and its 200-day simple moving average is $6.62. Sera Prognostics has a 12-month low of $3.84 and a 12-month high of $12.36.

Insider Transactions at Sera Prognostics

In other news, General Counsel Benjamin Jackson sold 7,912 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $6.38, for a total transaction of $50,478.56. Following the transaction, the general counsel now directly owns 120,561 shares in the company, valued at approximately $769,179.18. This trade represents a 6.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Joshua Phillips sold 12,710 shares of the stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $7.40, for a total transaction of $94,054.00. Following the transaction, the director now owns 5 shares in the company, valued at approximately $37. This represents a 99.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 69,877 shares of company stock valued at $480,677. 15.80% of the stock is currently owned by company insiders.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.